Dakatavir

Related products

• 

  Hepatitis C

  Popreway

  【Product name】VICTRELIS

  [English common name]Boceprevir

  [Chinese common name]Posipwe

  [English name]Boceprevir metabolites

  [Chinese other name]Bosipevir

  [Indications] VICTRELIS is a kindHepatitis CViral (HCV) NS3/4A protease inhibitors are indicated for the treatment of chronic hepatitis C (CHC) in combination with peginterferon alfa and ribavirin genotype 1 in patients with compensatory liver disease ( ≥18 years old) Adult patients, including cirrhosis, previously untreated or previously treated with interferon and ribavirin have failed.

  [Usage and Dosage] 800mg orally three times a day (every 7-9 hours) with food (a meal or snack).
  (1) VICTRELIS must be administered in combination with peginterferon alfa and ribavirin.
  (2) Refer to the peginterferon alfa and ribavirin package inserts for specific administration guidelines.

  [Storage] Store in the refrigerator (2 ° C – 8 ° C). Stored in the refrigerator by the patient (2 ° C – 8 ° C) until expiration. Either store outside the refrigerator at 30 ° C or below for no more than 3 months until expiration. After this, the medicine should be treated. Store in original blister to protect against moisture.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Hepatitis C

  Tiravir

  【Product name】INCIVEK

  [English common name]Telaprevir

  [Chinese common name]Tiravir

  [English name]VX-950, Telaprevir, LY 570310

  [Chinese other name]Trapivir

  [Indications] INCIVEK is a kindHepatitis CViral (HCV) NS3/4A protease inhibitor is indicated for use in combination with peginterferon alfa and ribavirin for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, Includes cirrhosis, untreated patients or patients who have previously been treated with interferon-based therapy, including those with previous zero response (Note: Hepatitis C virus load during treatment is minimal or no reduction), partial responders, and relapse By.
  (1) INCIVEK must not be used as a monotherapy and must be used only in combination with peginterferon alfa and ribavirin.
  (2) A high proportion of patients with previous zero response (especially those with cirrhosis) did not achieve sustained virological response (SVR) and there was a presence of telaprevir for treatment with INCIVEK with drug resistance.
  (3) The efficacy of INCIVEK has not been determined in patients who have previously failed treatment with INCIVEK or other HCV NS3/4A protease inhibitor regimens.

  【Dosage】
  (1) 750 mg 3 times a day (interval 7-9 hours) and food (not low fat).
  (2) For all patients, INCIVEK must be administered with both peginterferon alfa and ribavirin for a total of 12 weeks, followed by a reaction-guided regimen or 12 or 36 additional weeks of peginterferon alfa and ribba Welmin relies on viral reactions and previous reaction states.
  (3) For specific dosage instructions for peginterferon alfa and ribavirin, refer to their corresponding prescription materials.

  [Storage]Stored at 25oC (77oF); Allows an offset of 15-30oC (59-86oF).

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Hepatitis C

  Sofbwe

  【Product name】SOVALDI, Hepcinat

  [English common name]Sofosbuvir

  [Chinese common name]Sofbwe

  [English name]GS-7977, SOFOSBUVIR

  [Chinese other name]

  [Indications] Sofibuvir is a kindHepatitis CThe viral (HCV) nucleotide analog NS5B polymerase inhibitor is useful as a combination component in the treatment of chronic hepatitis C (CHC) infection as a combined antiviral treatment regimen. Sofite has been shown to be effective in treating patients with hepatitis C, 1, 2, 3 or 4, including hepatocellular carcinoma subjects who are awaiting liver transplantation in accordance with Milan standards, and HCV/HIV-1 co-infected subjects.

  [Usage and Dosage] 400mg per tablet, one tablet a day, fasting or with meals can be combined with ribavirin or combined with ribavirin + peginterferon to treat chronic hepatitis C (CHC).
  The recommended combination treatment plan is as follows:
  HCV infection alone or HCV / HIV-1 co-infection treatment regimen, duration of treatment
  Gene 1 or 4 sofosbuvir + peginterferon-α + ribavirin, 12 weeks
  Gene type 2 sofobuvir + ribavirin, 12 weeks
  Gene type 3 sofobuvir + ribavirin, 24 weeks
  Patients with type 1 chronic hepatitis C who are unable to use interferon may be treated with sofosbuvir plus ribavirin for 24 weeks.
  Patients with hepatocellular carcinoma waiting for liver transplantation should be treated with sofosbuvir plus ribavirin for 48 weeks or until liver transplantation, whichever occurs first.
  Dosage recommendations are not available for patients with severe renal impairment or with end-stage renal disease.

  [Storage]It is valid for two years, no refrigeration, and it can be stored at room temperature.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.